Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study

Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study

ObjectiveTo investigate whether extending adjuvant temozolomide (TMZ) improved the prognosis of newly diagnosed glioblastoma (GBM) patients with different mutation statuses of O6-methylguanine DNA methyltransferase (MGMT), isocitrate dehydrogenase 1 (IDH1), p53 and different expression level of Ki67...

Full description

Bibliographic Details
Main Authors: Jie Chen, Tingting Wang, Wanming Liu, Hui Qiu, Nie Zhang, Xueting Chen, Xin Ding, Longzhen Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
glioblastoma
extended adjuvant temozolomide
MGMT methylation
IDH1 mutation
prognosis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1000501/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1000501/full

Similar Items